The research has demonstrated that capmatinib, when administered as a first-line treatment for NSCLC with MET exon 14 skipping mutations, yields a superior tumor response, a reduced risk of disease progression, and an extended survival rate compared to regimens based on chemotherapy and immunotherapy (Wu Y. et al., 2021; Dong et al., 2022). This evidence concerns the gene MET and neoplasm.